CN118937702A - A new testosterone sample releaser formulation - Google Patents
A new testosterone sample releaser formulation Download PDFInfo
- Publication number
- CN118937702A CN118937702A CN202411009921.4A CN202411009921A CN118937702A CN 118937702 A CN118937702 A CN 118937702A CN 202411009921 A CN202411009921 A CN 202411009921A CN 118937702 A CN118937702 A CN 118937702A
- Authority
- CN
- China
- Prior art keywords
- testosterone
- buffer
- acid
- releaser
- formulation
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- MUMGGOZAMZWBJJ-DYKIIFRCSA-N Testostosterone Chemical compound O=C1CC[C@]2(C)[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 MUMGGOZAMZWBJJ-DYKIIFRCSA-N 0.000 title claims abstract description 118
- 229960003604 testosterone Drugs 0.000 title claims abstract description 59
- 239000000203 mixture Substances 0.000 title claims description 9
- 238000009472 formulation Methods 0.000 title description 6
- 239000003795 chemical substances by application Substances 0.000 claims abstract description 23
- FYEOMZSZJFOTGQ-GXWGVVPNSA-N (2z,8r,9s,10r,13s,14s,17r)-17-ethynyl-17-hydroxy-2-(hydroxymethylidene)-10,13-dimethyl-1,6,7,8,9,11,12,14,15,16-decahydrocyclopenta[a]phenanthren-3-one Chemical compound O=C1\C(=C/O)C[C@]2(C)[C@H]3CC[C@](C)([C@](CC4)(O)C#C)[C@@H]4[C@@H]3CCC2=C1 FYEOMZSZJFOTGQ-GXWGVVPNSA-N 0.000 claims abstract description 16
- 239000003153 chemical reaction reagent Substances 0.000 claims abstract description 14
- 238000003018 immunoassay Methods 0.000 claims abstract description 8
- 239000007853 buffer solution Substances 0.000 claims abstract description 4
- 239000000872 buffer Substances 0.000 claims description 14
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 claims description 6
- NUFBIAUZAMHTSP-UHFFFAOYSA-N 3-(n-morpholino)-2-hydroxypropanesulfonic acid Chemical compound OS(=O)(=O)CC(O)CN1CCOCC1 NUFBIAUZAMHTSP-UHFFFAOYSA-N 0.000 claims description 4
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 claims description 2
- IVLXQGJVBGMLRR-UHFFFAOYSA-N 2-aminoacetic acid;hydron;chloride Chemical compound Cl.NCC(O)=O IVLXQGJVBGMLRR-UHFFFAOYSA-N 0.000 claims description 2
- 239000007979 citrate buffer Substances 0.000 claims description 2
- 239000007974 sodium acetate buffer Substances 0.000 claims description 2
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 claims 2
- HNXGGWNCFXZSAI-UHFFFAOYSA-N 2-morpholin-2-ylethanesulfonic acid Chemical compound OS(=O)(=O)CCC1CNCCO1 HNXGGWNCFXZSAI-UHFFFAOYSA-N 0.000 claims 1
- BHZOKUMUHVTPBX-UHFFFAOYSA-M sodium acetic acid acetate Chemical compound [Na+].CC(O)=O.CC([O-])=O BHZOKUMUHVTPBX-UHFFFAOYSA-M 0.000 claims 1
- 230000003578 releasing effect Effects 0.000 description 16
- 238000012360 testing method Methods 0.000 description 12
- 238000001514 detection method Methods 0.000 description 8
- NVKAWKQGWWIWPM-ABEVXSGRSA-N 17-β-hydroxy-5-α-Androstan-3-one Chemical compound C1C(=O)CC[C@]2(C)[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CC[C@H]21 NVKAWKQGWWIWPM-ABEVXSGRSA-N 0.000 description 7
- 229960003473 androstanolone Drugs 0.000 description 7
- RJKFOVLPORLFTN-LEKSSAKUSA-N Progesterone Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H](C(=O)C)[C@@]1(C)CC2 RJKFOVLPORLFTN-LEKSSAKUSA-N 0.000 description 6
- 229920000669 heparin Polymers 0.000 description 6
- ZFGMDIBRIDKWMY-PASTXAENSA-N heparin Chemical compound CC(O)=N[C@@H]1[C@@H](O)[C@H](O)[C@@H](COS(O)(=O)=O)O[C@@H]1O[C@@H]1[C@@H](C(O)=O)O[C@@H](O[C@H]2[C@@H]([C@@H](OS(O)(=O)=O)[C@@H](O[C@@H]3[C@@H](OC(O)[C@H](OS(O)(=O)=O)[C@H]3O)C(O)=O)O[C@@H]2O)CS(O)(=O)=O)[C@H](O)[C@H]1O ZFGMDIBRIDKWMY-PASTXAENSA-N 0.000 description 6
- 229960001008 heparin sodium Drugs 0.000 description 6
- POZRVZJJTULAOH-LHZXLZLDSA-N danazol Chemical compound C1[C@]2(C)[C@H]3CC[C@](C)([C@](CC4)(O)C#C)[C@@H]4[C@@H]3CCC2=CC2=C1C=NO2 POZRVZJJTULAOH-LHZXLZLDSA-N 0.000 description 5
- 229960000766 danazol Drugs 0.000 description 5
- 230000000694 effects Effects 0.000 description 5
- 102000009027 Albumins Human genes 0.000 description 4
- 108010088751 Albumins Proteins 0.000 description 4
- 108091008361 cortisol binding proteins Proteins 0.000 description 4
- 239000003163 gonadal steroid hormone Substances 0.000 description 4
- 108091011044 hormone binding proteins Proteins 0.000 description 4
- 102000036124 hormone binding proteins Human genes 0.000 description 4
- 239000000186 progesterone Substances 0.000 description 3
- 229960003387 progesterone Drugs 0.000 description 3
- 230000035945 sensitivity Effects 0.000 description 3
- 210000002966 serum Anatomy 0.000 description 3
- 150000003431 steroids Chemical class 0.000 description 3
- SXGZJKUKBWWHRA-UHFFFAOYSA-N 2-(N-morpholiniumyl)ethanesulfonate Chemical compound [O-]S(=O)(=O)CC[NH+]1CCOCC1 SXGZJKUKBWWHRA-UHFFFAOYSA-N 0.000 description 2
- 102000002260 Alkaline Phosphatase Human genes 0.000 description 2
- 108020004774 Alkaline Phosphatase Proteins 0.000 description 2
- 208000014311 Cushing syndrome Diseases 0.000 description 2
- 208000037171 Hypercorticoidism Diseases 0.000 description 2
- 239000007987 MES buffer Substances 0.000 description 2
- 201000005255 adrenal gland hyperfunction Diseases 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 230000002255 enzymatic effect Effects 0.000 description 2
- 150000002391 heterocyclic compounds Chemical class 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 201000002909 Aspergillosis Diseases 0.000 description 1
- 208000036641 Aspergillus infections Diseases 0.000 description 1
- 206010010356 Congenital anomaly Diseases 0.000 description 1
- 206010011498 Cryptorchism Diseases 0.000 description 1
- OKJCFMUGMSVJBG-ABEVXSGRSA-N Delta(1)-dihydrotestosterone Chemical compound C1C(=O)C=C[C@]2(C)[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CC[C@H]21 OKJCFMUGMSVJBG-ABEVXSGRSA-N 0.000 description 1
- 206010020112 Hirsutism Diseases 0.000 description 1
- 208000007641 Pinealoma Diseases 0.000 description 1
- 208000024313 Testicular Neoplasms Diseases 0.000 description 1
- 230000005856 abnormality Effects 0.000 description 1
- 201000002454 adrenal cortex cancer Diseases 0.000 description 1
- 230000001919 adrenal effect Effects 0.000 description 1
- 210000004100 adrenal gland Anatomy 0.000 description 1
- 239000000427 antigen Substances 0.000 description 1
- 102000036639 antigens Human genes 0.000 description 1
- 108091007433 antigens Proteins 0.000 description 1
- 238000003149 assay kit Methods 0.000 description 1
- 239000011324 bead Substances 0.000 description 1
- 238000004140 cleaning Methods 0.000 description 1
- 230000001054 cortical effect Effects 0.000 description 1
- 201000000160 cryptorchidism Diseases 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 238000007865 diluting Methods 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 210000000918 epididymis Anatomy 0.000 description 1
- 201000010063 epididymitis Diseases 0.000 description 1
- 229940011871 estrogen Drugs 0.000 description 1
- 239000000262 estrogen Substances 0.000 description 1
- DBLXOVFQHHSKRC-UHFFFAOYSA-N ethanesulfonic acid;2-piperazin-1-ylethanol Chemical compound CCS(O)(=O)=O.OCCN1CCNCC1 DBLXOVFQHHSKRC-UHFFFAOYSA-N 0.000 description 1
- 210000004392 genitalia Anatomy 0.000 description 1
- 206010020718 hyperplasia Diseases 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 210000002570 interstitial cell Anatomy 0.000 description 1
- 239000006249 magnetic particle Substances 0.000 description 1
- 239000010413 mother solution Substances 0.000 description 1
- 208000025189 neoplasm of testis Diseases 0.000 description 1
- 230000002611 ovarian Effects 0.000 description 1
- 210000001672 ovary Anatomy 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 208000024724 pineal body neoplasm Diseases 0.000 description 1
- 201000010065 polycystic ovary syndrome Diseases 0.000 description 1
- 208000006155 precocious puberty Diseases 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 210000001625 seminal vesicle Anatomy 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 201000003120 testicular cancer Diseases 0.000 description 1
- 210000001550 testis Anatomy 0.000 description 1
- WJCNZQLZVWNLKY-UHFFFAOYSA-N thiabendazole Chemical compound S1C=NC(C=2NC3=CC=CC=C3N=2)=C1 WJCNZQLZVWNLKY-UHFFFAOYSA-N 0.000 description 1
- 210000001177 vas deferen Anatomy 0.000 description 1
- 201000010653 vesiculitis Diseases 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/74—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving hormones or other non-cytokine intercellular protein regulatory factors such as growth factors, including receptors to hormones and growth factors
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N21/00—Investigating or analysing materials by the use of optical means, i.e. using sub-millimetre waves, infrared, visible or ultraviolet light
- G01N21/75—Systems in which material is subjected to a chemical reaction, the progress or the result of the reaction being investigated
- G01N21/76—Chemiluminescence; Bioluminescence
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Biomedical Technology (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Medicinal Chemistry (AREA)
- Cell Biology (AREA)
- Microbiology (AREA)
- Biotechnology (AREA)
- Food Science & Technology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Plasma & Fusion (AREA)
- Endocrinology (AREA)
- Steroid Compounds (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Investigating Or Analysing Materials By The Use Of Chemical Reactions (AREA)
Abstract
本发明免疫分析技术领域，具体涉及一种睾酮免疫检测试剂样本释放剂配方。本发明公开了一种睾酮免疫检测试剂样本释放剂配方，其组成成分：2‑HydroxymethyleneEthisterone(CAS:2787‑02‑2)溶解于缓冲液中。
The present invention relates to the field of immunoassay technology, and specifically to a testosterone immunoassay reagent sample release agent formula. The present invention discloses a testosterone immunoassay reagent sample release agent formula, and its components are: 2-Hydroxymethylene Ethisterone (CAS: 2787-02-2) is dissolved in a buffer solution.
Description
Technical Field
The invention belongs to the technical field of immunoassay, and particularly relates to a novel sample releasing agent formula of testosterone.
Background
Testosterone, also known as testosterone, testosterone or testosterone, is a steroid estrogen secreted by the testes of men or the ovaries of women, and small amounts of testosterone are also secreted by the adrenal glands. Testosterone can promote the formation of epididymis, vas deferens and seminal vesicles, promote the growth and development of external genitalia and secondary sex characteristics, influence the formation of sperms, and has important effects on health of men or women. For men, the increase in testosterone levels is common in conditions such as adrenal cortical hyperplasia, adrenal cortical tumor, testicular tumor, male sexual precocity, etc. However, reduced testosterone levels are common in primary male hypofunction, such as cryptorchidism, testosterone-free, interstitial cell hypoplasia, congenital aspergillosis, and the like, as well as in conditions such as hypercortisolism, and hypercortisolism. For females, abnormalities in testosterone levels are common in idiopathic hirsutism, polycystic ovary syndrome, pineal tumor, ovarian males, and the like. Accurate detection of testosterone levels in vivo is helpful in the assisted diagnosis and treatment of these diseases.
In serum, testosterone binds mainly to sex hormone binding protein, albumin and cortisol binding protein, with only 2% of testosterone being in the free state. The immunological detection of serum total testosterone requires the release of testosterone from sex hormone binding protein, albumin and cortisol binding protein to facilitate detection of antibody recognition. Therefore, the composition of the testosterone release reagent in the detection reagent is related to the testosterone release effect, and the sensitivity and the specificity of the serum total testosterone immunodetection reagent are directly affected. At present, a commercial TESTO reagent has a corresponding testosterone releasing agent, but a new more effective testosterone releasing agent formula is found in the research, so that the sensitivity and the specificity of the reagent can be better improved.
Disclosure of Invention
The purpose of the invention is that: it is intended to provide a more effective testosterone-releasing agent formulation.
In order to achieve the technical purpose, the invention adopts the following technical scheme:
A testosterone immunodetection reagent sample release agent formula comprises the following key components: 2-HydroxymethyleneEthisterone (CAS: 2787-02-2) in a buffer. The buffer may be any one of PBS buffer, 2-morpholinoethanesulfonic acid buffer (MES), TRIS-HCL buffer, citrate buffer, 3- (N-morpholino) -2-hydroxy propane sulfonic acid (MOPSO) buffer, glycine-hydrochloric acid buffer, sodium acetate buffer, 4-hydroxyethylpiperazine ethanesulfonic acid (HEPES) buffer.
As a preferred embodiment of the present invention, the testosterone releasing agent comprises a concentration of 2-HydroxymethyleneEthisterone (CAS: 2787-02-2) components: 0.01-0.5mg/mL.
The preparation method of the testosterone release agent comprises the following steps:
S1, taking a compound with testosterone releasing effect according to the component proportion, and dissolving the compound with DMSO or DMF or pure water to prepare a mother solution with the concentration of 500 mg/mL.
S2, diluting the testosterone to a corresponding concentration through buffer solution to prepare the testosterone release reagent.
Compared with the prior art, the technical scheme of the invention has the advantages that the releasing agent in the detection reagent is used as a component part of the testosterone enzymatic chemiluminescence immunoassay reagent, so that testosterone can be more effectively dissociated from the binding egg, and the sensitivity and specificity of the testosterone immunoassay reagent can be obviously improved.
Drawings
The invention can be further illustrated by means of non-limiting examples given in the accompanying drawings;
FIG. 1 is a graph of the results of a test of a reference example without testosterone releasing agent;
FIG. 2 is a graph showing the results of a test of progesterone as a reference example of testosterone releasing agent;
FIG. 3 is a graph showing the results of testing a reference example of dihydrotestosterone as a testosterone releasing agent;
FIG. 4 is a graph showing the results of testing of reference examples of dihydrotestosterone, heparin sodium, danazol as testosterone releasing agent;
FIG. 5 is a graph of the detection results of example 1;
FIG. 6 is a graph of the detection results of example 2;
FIG. 7 shows the test result of example 3.
Detailed Description
In order that those skilled in the art will better understand the present invention, the following technical scheme of the present invention will be further described with reference to the accompanying drawings and examples.
Taking testosterone magnetic particle enzymatic chemiluminescence immunoassay reagents as an example, the composition of the kit comprises: superparamagnetic particles coated with testosterone antigen, alkaline phosphatase-labeled testosterone antibody, testosterone release agent, alkaline phosphatase luminescent substrate and magnetic bead cleaning solution;
The testosterone release agent is characterized by 2-HydroxymethyleneEthisterone (CAS: 2787-02-2) dissolved in a buffer.
Example 1 testosterone sample release formulation 1 comprising the following components: 50mM PB S buffer, pH 7.0, containing 0.2m g/m L2-HydroxymethyleneEthisterone (CAS: 2787-02-2);
Example 2 testosterone sample release formulation 2 comprising the following components: 50mM MES buffer, pH6.0, containing 0.2m g/m L2-HydroxymethyleneEthisterone (CAS: 2787-02-2), 5mg/mL heparin sodium;
Example 3 testosterone sample release formulation 3 comprising the following components: 50mM MES buffer, pH6.0, containing 0.2mg/mL 2-HydroxymethyleneEthisterone (CAS: 2787-02-2), 5mg/mL heparin sodium, 0.02mg/mL danazol.
Specificity: a clinical sample was collected 40 and the samples were tested with testosterone assay kits for different sample release formulations of examples 1-3, respectively, and the test results were compared to clinical test results, see fig. 1-7.
Fig. 1 is a graph showing the results of the test of a reference example without testosterone releasing agent, fig. 2 is a graph showing the results of the test of a steroid heterocyclic compound progesterone as testosterone releasing agent, fig. 3 is a graph showing the results of the test of a reference example with dihydrotestosterone as testosterone releasing agent, and fig. 4 is a graph showing the results of the test of a reference example with dihydrotestosterone, heparin sodium, danazol as testosterone releasing agent at the same time; fig. 5 to 7 are graphs showing the detection results of examples 1 to 3, respectively.
The experimental result of fig. 1 shows that the linear equation is y=0.8722 x+1.4482, and the correlation coefficient is R 2 = 0.5271;
the experimental result of fig. 2 shows that the linear equation is y=0.8864x+1.6093, and the correlation coefficient is R 2 = 0.6451;
The experimental result of fig. 3 shows that the linear equation is y=1.0022x+0.1944, and the correlation coefficient is R 2 =0.9729;
The experimental result of fig. 4 shows that the linear equation is y= 1.0227x-0.0606, and the correlation coefficient is R 2 = 0.9865;
The experimental result of fig. 5 shows that the linear equation is y= 0.9937x-0.0165, and the correlation coefficient is R 2 = 0.9762;
the experimental result of fig. 6 shows that the linear equation is y=0.9741x+0.0358, and the correlation coefficient is R 2 = 0.9898;
The experimental results of fig. 7 show that the linear equation is y=0.9789x+0.0522, and the correlation coefficient is R 2 = 0.9936.
Through figures 1,2 and 3, the steroid heterocyclic compound progesterone does not have a testosterone molecule release effect, and the dihydrotestosterone can more fully promote the testosterone molecule release. Dihydrotestosterone is capable of competitively binding to sex hormone binding protein, thereby releasing testosterone molecules that bind to sex hormone binding protein, but a portion of testosterone molecules still bind to albumin and cortisol binding protein. Whereas heparin sodium and danazol release testosterone molecules from albumin and cortisol binding protein binding, respectively. A comparison of fig. 3 and 4 demonstrates the effect of heparin sodium and danazol. And figure 5 shows that the effect of testosterone release in the presence of only 2-HydroxymethyleneEthisterone (CAS: 2787-02-2) is superior to that of dihydrotestosterone alone as testosterone release agent.
The above embodiments are merely illustrative of the principles of the present invention and its effectiveness, and are not intended to limit the invention. Modifications and variations may be made to the above-described embodiments by those skilled in the art without departing from the spirit and scope of the invention. Accordingly, it is intended that all equivalent modifications and variations of the invention be covered by the claims of this invention, which are within the skill of those skilled in the art, can be made without departing from the spirit and scope of the invention disclosed herein.
Claims (1)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202411009921.4A CN118937702A (en) | 2021-08-04 | 2021-08-04 | A new testosterone sample releaser formulation |
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202411009921.4A CN118937702A (en) | 2021-08-04 | 2021-08-04 | A new testosterone sample releaser formulation |
| CN202110892227.1A CN113624982B (en) | 2021-08-04 | 2021-08-04 | A magnetic particle enzymatic chemiluminescent immunoassay reagent for testosterone |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202110892227.1A Division CN113624982B (en) | 2021-08-04 | 2021-08-04 | A magnetic particle enzymatic chemiluminescent immunoassay reagent for testosterone |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN118937702A true CN118937702A (en) | 2024-11-12 |
Family
ID=78382765
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202411009750.5A Pending CN119125584A (en) | 2021-08-04 | 2021-08-04 | A testosterone immunoassay reagent sample release agent formula |
| CN202411009921.4A Pending CN118937702A (en) | 2021-08-04 | 2021-08-04 | A new testosterone sample releaser formulation |
| CN202110892227.1A Active CN113624982B (en) | 2021-08-04 | 2021-08-04 | A magnetic particle enzymatic chemiluminescent immunoassay reagent for testosterone |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202411009750.5A Pending CN119125584A (en) | 2021-08-04 | 2021-08-04 | A testosterone immunoassay reagent sample release agent formula |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202110892227.1A Active CN113624982B (en) | 2021-08-04 | 2021-08-04 | A magnetic particle enzymatic chemiluminescent immunoassay reagent for testosterone |
Country Status (1)
| Country | Link |
|---|---|
| CN (3) | CN119125584A (en) |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE3650437T2 (en) * | 1985-10-04 | 1996-04-18 | Diagnostic Products Corp | Method for measuring free ligands in biological liquids. |
| CN103954779B (en) * | 2014-03-12 | 2015-09-16 | 长春迪瑞医疗科技股份有限公司 | A kind of testosterone based on microparticle chemiluminescence immunoassay technology detects reagent |
| CN108982880A (en) * | 2018-05-31 | 2018-12-11 | 湖南远璟生物技术有限公司 | A kind of testosterone magnetic microparticle chemiluminescence immune quantitative detection reagent box and preparation method thereof |
| CN110579615A (en) * | 2019-09-06 | 2019-12-17 | 广州科方生物技术股份有限公司 | Release agent universal for steroid hormone in serum and preparation method thereof |
| CN112394182A (en) * | 2020-10-29 | 2021-02-23 | 深圳市辰纳生物科技有限公司 | Estradiol release reagent and detection kit thereof |
-
2021
- 2021-08-04 CN CN202411009750.5A patent/CN119125584A/en active Pending
- 2021-08-04 CN CN202411009921.4A patent/CN118937702A/en active Pending
- 2021-08-04 CN CN202110892227.1A patent/CN113624982B/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| CN113624982A (en) | 2021-11-09 |
| CN113624982B (en) | 2024-11-26 |
| CN119125584A (en) | 2024-12-13 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| KR101840525B1 (en) | Vitamin d measurement method and measurement kit | |
| US20130011932A1 (en) | Reagent composition for immunochromatography | |
| Rota et al. | Age dependent changes in plasma anti-Müllerian hormone concentrations in the bovine male, female, and freemartin from birth to puberty: relationship between testosterone production and influence on sex differentiation | |
| JP7194114B2 (en) | Treatment liquid for uninclusion of steroids clathrated in cyclodextrin | |
| JP3486411B2 (en) | Measurement of estradiol by competitive immunoassay | |
| CN112394182A (en) | Estradiol release reagent and detection kit thereof | |
| JPH11501397A (en) | Determination of steroid by competitive immunoassay | |
| Dufour et al. | Development and validation of a liquid chromatography coupled to mass spectrometer (LC-MS) method for the simultaneous quantification of estrone-3-sulfate, progesterone, estrone and estradiol in serum of mares and American bisons | |
| VEYSSIERE et al. | Levels of testosterone in the plasma, gonads, and adrenals during fetal development of the rabbit | |
| Legacki et al. | Concentrations of sulphated estrone, estradiol and dehydroepiandrosterone measured by mass spectrometry in pregnant mares | |
| JP6934587B2 (en) | Method for measuring steroid hormones in samples | |
| CN118937702A (en) | A new testosterone sample releaser formulation | |
| JP6330666B2 (en) | Target substance measurement method | |
| CN109212196A (en) | A kind of kit of quick detection free estriol | |
| Dechaud et al. | New approach to competitive lanthanide immunoassay: time-resolved fluoroimmunoassay of progesterone with labeled analyte. | |
| JP7568634B2 (en) | Method for measuring steroids in urine samples, and kit and neutralizing solution for measuring steroids in urine samples for use therein | |
| US4740476A (en) | Immunoassay for estriol-3-sulfate | |
| EP2742352B1 (en) | Detection of sex steroids | |
| Ayad et al. | The ability of human electrochemiluminescence immunoassay to measure testosterone and progesterone in ovine plasma. | |
| Sakurada et al. | Identification of vaginal stains by detection of 17 β-estradiol | |
| Saksena et al. | Determination of seven unconjugated steroids in the blood and seminal plasma of the fertile male rabbit | |
| Gower | Analysis of androgens and their derivatives | |
| Rao et al. | Specific antisera suitable for solid-phase radioimmunoassay of 11β-hydroxyandrost-4-ene-3, 17-dione | |
| JPS62171698A (en) | Testosterone immunological measurement method and reagent, monoclonal antibody and its production method, hybridoma cell line | |
| JPH06102275A (en) | How to measure steroid hormones |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination |